Analysts at B. Riley initiated coverage on shares of Agenus (NASDAQ:AGEN) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. B. Riley’s price objective indicates a potential upside of 37.61% from the stock’s current price.
AGEN has been the topic of several other reports. ValuEngine upgraded Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. BidaskClub upgraded Agenus from a “sell” rating to a “hold” rating in a report on Monday, November 11th.
Shares of NASDAQ:AGEN traded down $0.04 during midday trading on Tuesday, hitting $4.36. 2,182,633 shares of the stock were exchanged, compared to its average volume of 1,200,474. The stock has a market capitalization of $510.98 million, a price-to-earnings ratio of -3.03 and a beta of 1.84. The business’s 50-day moving average price is $2.88 and its 200 day moving average price is $2.79. Agenus has a 12 month low of $1.95 and a 12 month high of $4.57.
Several large investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System grew its holdings in shares of Agenus by 19.6% during the third quarter. California Public Employees Retirement System now owns 184,639 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 30,318 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in Agenus in the third quarter valued at approximately $27,000. Cambridge Investment Research Advisors Inc. bought a new stake in Agenus in the second quarter valued at approximately $40,000. UBS Asset Management Americas Inc. boosted its holdings in Agenus by 8.0% in the second quarter. UBS Asset Management Americas Inc. now owns 149,824 shares of the biotechnology company’s stock valued at $449,000 after acquiring an additional 11,100 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Agenus in the second quarter valued at approximately $225,000. Institutional investors own 36.69% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
See Also: What are earnings reports?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.